Ask about this productRelated genes to: Reck antibody
- Gene:
- RECK NIH gene
- Name:
- reversion inducing cysteine rich protein with kazal motifs
- Previous symbol:
- ST15
- Synonyms:
- hRECK
- Chromosome:
- 9p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-10-30
- Date modifiied:
- 2016-01-28
Related products to: Reck antibody
Related articles to: Reck antibody
- To characterise the clinical and genetic profile of adult familial Mediterranean fever (FMF) patients at a German tertiary referral centre and examine genotype-phenotype associations. - Source: PubMed
Publication date: 2026/08/28
Reck DorotheaHenes Jörg ChristophSaur Sebastian Jonas - In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (EFS) and pathologic complete response in patients with resectable non-small cell lung cancer (R-NSCLC), with a safety profile consistent with the individual agents. We report EFS from a second planned interim analysis, interim disease-free survival (DFS) and overall survival (OS), and safety, after all patients completed/discontinued treatment. In this phase III, double-blind, placebo-controlled study, patients with treatment-naïve R-NSCLC (stage II-IIIB [N2]) were randomly assigned (1:1) to neoadjuvant platinum-based chemotherapy plus durvalumab/placebo (once every 3 weeks, four cycles) presurgery and then adjuvant durvalumab/placebo (once every 4 weeks, 12 cycles). Efficacy was analyzed in the modified intention-to-treat population (n = 740; for DFS, its resected subpopulation), which excluded patients with documented / aberrations. As of May 10, 2024 (median follow-up, 25.9 months [censored patients]), EFS benefit favoring the durvalumab arm remained consistent (hazard ratio [HR], 0.69 [95% CI, 0.55 to 0.88]). Numerical improvement in DFS (HR, 0.66 [95% CI, 0.47 to 0.92]) and OS (HR, 0.89 [95% CI, 0.70 to 1.14]) favored the durvalumab arm. Maximum grade 3/4 adverse events occurred in 15.4% and 10.6% of the durvalumab and placebo arms, respectively, during adjuvant treatment. These results further support perioperative durvalumab plus neoadjuvant chemotherapy as a new treatment option. - Source: PubMed
Publication date: 2026/08/28
Heymach John VHe JieHarpole DavidMitsudomi TetsuyaTaube Janis MGao ShugengUrban LaszloKang Jin HyoungOrlandi Francisco JRodriguez-Cid JeronimoMassuti BartomeuMateos Luis LeonPasello GiuliaChu QuincyKolb-Sielecki JaroslawNakata MasaoGalffy GabriellaHochmair MaximilianWinder ThomasZukov RuslanGarbaos GabrielHorio YoshitsuguOstoros GyulaTran Tho VYou JianLee Kang-YunAntonuzzo LorenzoAkamatsu HiroakiBiswas BivasSpira AlexanderCrawford JeffreyLe Ha TAperghis MikeMann HelenFouad Tamer MDoherty Gary JReck Martin - Dental follicle cells (DFCs) are promising candidates for regenerative medicine due to their osteogenic potential. While the protein kinase C (PKC) inhibitor Gö6976 is known to enhance DFC differentiation, the underlying molecular mechanisms remain partially understood. A phosphoproteomic analysis of DFCs after 14 days of osteogenic induction was performed. Cells treated with osteogenic differentiation medium (ODM) were compared to those in control medium and ODM supplemented with Gö6976. Reactome pathway analysis identified the RhoGTPase signaling pathway as significantly regulated. This pathway was further validated using PCR arrays, Western blotting, and functional assays (ALP activity, Alizarin Red staining). The impact of RhoGTPase signaling was tested using inhibitors (NSC23766, Y27632, Rhosin) and the activator Geranylgeranyl pyrophosphate (GGPP). Phosphoproteomic data highlighted RhoGTPase signaling as a regulatory node. While protein expression of RhoGTPases remained relatively stable, RhoA PCR arrays revealed significant transcriptional regulation after induction of osteogenic differentiation. However, functional inhibition via NSC, Y27632, or Rhosin did not significantly impair basal ODM-induced differentiation; however, Y27632 notably induced SOST expression. Conversely, activation of RhoGTPases via GGPP increased ALP activity and downregulated SOST, suggesting a supportive role of active Rho signaling during differentiation. Crucially, we demonstrated that Gö6976-enhanced mineralization is linked to the activation of RhoA and RhoB. This was confirmed by simvastatin-mediated regulation of Rho expression, which was fully reversed by simultaneous treatment with Gö6976. Furthermore, Rhosin effectively counteracted the pro-osteogenic effects of Gö6976 by inhibiting ALP activity and mineralization while inducing SOST, which is normally suppressed by Gö6976. These findings indicate that RhoGTPase signaling, particularly RhoA, is a critical downstream mediator required specifically for the Gö6976-enhanced osteogenic effect in DFCs. We conclude that Gö6976 exerts its stimulatory effect on mineralization by activating RhoGTPases and suppressing the osteogenesis inhibitor SOST, providing a context-dependent mechanism for accelerated differentiation rather than driving basal osteogenesis. - Source: PubMed
Publication date: 2026/08/06
Morsczeck ChristianReck AnjaBodensteiner TheresaReichert Torsten EBeck Hans Christian - The unique occupational conditions of seafaring are associated with increased physical and psychological stress and significantly complicate common approaches to health promotion and prevention. Digital health technologies are therefore considered promising alternatives that can better address barriers to access, infrastructural shortcomings and cultural diversity. - Source: PubMed
Publication date: 2026/08/26
Reck ChiaraBelz LukasDengler DorotheePuls Nora MariaHarth VolkerOldenburg Marcus - Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671 after 5 years of follow-up. - Source: PubMed
Publication date: 2026/08/21
Wakelee HSpicer J DGao SLiberman MTsuboi MKato TChen K-NDooms CMajem MMartinengo G LBylicki ORodríguez-Abreu DHalmos BJones D RChaft J EReck MJensen EKeller S MSamkari AGarassino M C